Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date † | August 31, 2005 | ||||
Last Updated Date | September 8, 2006 | ||||
Start Date † | January 2004 | ||||
Current Primary Outcome Measures † |
|
||||
Original Primary Outcome Measures † | Same as current | ||||
Change History | Complete list of historical versions of study NCT00142220 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures † |
|
||||
Original Secondary Outcome Measures † | Same as current | ||||
Descriptive Information | |||||
Brief Title † | The Benefit of Adding Fish Oil to the Nutrition of Critically Ill Patients | ||||
Official Title † | Comparison Between Two Different Proportions of Omega-3- and Omega-6-Fatty Acids in the Parenteral Nutrition of Critically Ill Patients | ||||
Brief Summary | We study whether an increased proportion of omega-3-fatty acids (contained in fish oil) in the nutrition of critically ill patients reduces systemic inflammation. |
||||
Detailed Description | |||||
Study Phase | Phase IV | ||||
Study Type † | Interventional | ||||
Study Design † | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study | ||||
Condition † | Sepsis Syndrome | ||||
Intervention † | Drug: Defined percentage of omega-3-fatty acids | ||||
Study Arms / Comparison Groups | |||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status † | Completed | ||||
Enrollment † | 160 | ||||
Completion Date | |||||
Primary Completion Date | |||||
Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | |||||
Accepts Healthy Volunteers | No | ||||
Contacts †† | |||||
Location Countries † | Germany | ||||
Expanded Access Status | |||||
Administrative Information | |||||
NCT ID † | NCT00142220 | ||||
Responsible Party | |||||
Secondary IDs †† | |||||
Study Sponsor † | Ernst Moritz Arndt University of Greifswald | ||||
Collaborators †† | Fresenius AG | ||||
Investigators † |
|
||||
Information Provided By | Ernst Moritz Arndt University of Greifswald | ||||
Verification Date | September 2006 | ||||
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |